Population-based outcomes of patients (pt) with early-stage HER2-positive breast cancer treated with adjuvant trastuzumab (T).

被引：0
|
作者：
Noonan, Krista
McCarthy, Joy S.
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
[2] Dr H Bliss Murphy Canc Ctr, St John, NF, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11079
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
    Iwata, Hiroji
    Masuda, Norikazu
    Kim, Sung-Bae
    Inoue, Kenichi
    Rai, Yoshiaki
    Fujita, Takashi
    Chiu, Joanne
    Ohtani, Shoichiro
    Takahashi, Masato
    Miyaki, Toshiko
    Lu, Yen-Shen
    Xu, Binghe
    Yap, Yoon Sim
    Bustam, Anita
    Yao, Bin
    Zhang, Bo
    Bryce, Richard
    Chan, Arlene
    FUTURE ONCOLOGY, 2019, 15 (21) : 2489 - 2501
  • [42] Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?
    Schwartz, Naomi R. M.
    Flanagan, Meghan Rose
    Babigumira, Joseph B.
    Steuten, Lotte Maria Gertruda
    Roth, Joshua A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting
    Murthy, Rashmi Krishna
    Varma, Ankur
    Mishra, Priyankana
    Hess, Kenneth R.
    Young, Elliana J.
    Murray, James L.
    Koenig, Kimberly Higginbotham
    Green, Marjorie C.
    Moulder, Stacy L.
    Melhem-Bertrandt, Amal
    Booser, Daniel J.
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab
    Yuri Torrejon, Davis
    Di Cosimo, Serena
    Sanchez-Olle, Gessami
    Balmana, Judith
    Bellet, Meritxell
    Gomez, Patricia
    Saura, Cristina
    Manuel Perez-Garcia, Jose
    Munoz-Couselo, Eva
    Vidal, Maria
    Ortega, Vanesa
    De Mattos-Arruda, Leticia
    Oliveira, Mafalda
    Mulet-Margalef, Nuria
    Tabernero, Josep
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] Advances in the Treatment of Early-Stage HER2-Positive Breast Cancer
    Sharifi, Marina
    Wisinski, Kari B.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (08) : 482 - 492
  • [46] Systemic therapy for HER2-positive early-stage breast cancer
    Mathew, Aju
    Romond, Edward H.
    CURRENT PROBLEMS IN CANCER, 2016, 40 (2-4) : 106 - 116
  • [47] Risk of Recurrence in Early-Stage, HER2-Positive Breast Cancer
    Isaacs, Claudine
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (08) : 3 - 6
  • [48] The Effect of Adding Pertuzumab to Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer
    Al-Azawi, Ahmed
    Hneua, Riyadh Abd-Alrasool
    Hameed, Rana Majeed
    Hassan, Duha Maithem
    JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (03): : 197 - 200
  • [49] Clinical outcomes of patients with recurrent HER2-positive breast cancer after exposure to adjuvant trastuzumab
    Mullins, D. N.
    Abdel-Rasoul, M.
    Querry, J.
    Akuma, D.
    Feng, A.
    Shapiro, C. L.
    Macrae, E.
    CANCER RESEARCH, 2013, 73
  • [50] Cost-effectiveness analysis (CEA) of adjuvant trastuzumab therapy use in HER2-positive early-stage breast cancer (EBC)
    Quintyne, K. I.
    Woulfe, B.
    Dee, A.
    Gupta, R.
    ANNALS OF ONCOLOGY, 2016, 27
12345